Sexually Transmitted Diseases
Treatment market - Regional Analysis
Geographically, the Sexually
Transmitted Diseases Treatment Market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is
expected to be dominant market, owing to rising government initiative for
disease awareness and implementation of prenatal screening programs. However,
Asia Pacific is expected to be fastest growing market for sexually transmitted
diseases treatment, due to high incidence of sexually transmitted infections,
owing to unprotected sexual practices in the region. For instance, according to
Joint United Nations Programme on HIV and AIDS (UNAIDS), Asia Pacific had the
second-highest number of people living with HIV in the world i.e. 5.1 million
as of 2016, Moreover, China, India, and Indonesia accounts for three quarters
of the total people living with HIV in Asia Pacific.
Sexually transmitted disease also
known as venereal diseases is a clinical syndrome of infection, acquired and
transmitted through sexual activity via body fluids such as semen, vaginal
fluid or blood. Causative agent of STD are bacteria, parasites, yeast, and
viruses. Symptoms of STDs includes skin rashes, warts, abdominal pain or
genital ulcers. STDs are detected by physical examination or assays such as
ELISA (Enzyme Linked Immunosorbent Assay), rapid plasma reagin blood test or
antibody-absorption blood test. The sexually transmitted disease treatment
market is expected to witness high growth in the forecast period (2017 – 2025),
due to the factors such as increasing disease burden, governmental initiatives
for increasing awareness, growing diagnosis of sexually transmitted diseases,
and increasing number of pipeline products by manufacturers for treatment of
these diseases.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2005
Sexually Transmitted Diseases
Treatment market – Driver
Increasing sexually transmitted
disease burden is fueling growth of the STDs treatment market. Among 20 STDs,
the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV),
and Human Immunodeficiency Virus (HIV). For instance, according to Centers for
Disease Control and Prevention (CDC), in year 2016, 1,598,354 cases of
Chlamydia trachomatis infection were reported in the U.S., corresponding to
497.3 cases per 100,000 in 2015. Furthermore, 468,514 gonorrhea cases were
reported for a rate of 145.8 cases per 100,000 population, an increase of 18.5%
from 2015. This increasing incidence of STDs is also due to the unprotected
sexual practice, which in turn fueling demand for STDs treatment. For instance,
according to World Health Organization (WHO), unsafe sex is second most common
risk factor for increasing disease burden.
The number of products in
pipeline for HIV treatment are high, which is expected to propel growth of the
sexually transmitted disease treatment market. For instance, in 2017, GSK and
ViiV Healthcare applied in European Medicines Agency (EMA) and US Food and Drug
Administration (FDA), for regulatory affiliation for a single-tablet, two-drug
regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used
for treatment of HIV-1 infection. Moreover, other drug candidates in pipeline
includes – PrEP, PRO140 with ibalizumab, BMS- 955176, which are expected to be
launched in the forecast period. Moreover, governments are focusing on funding
research and development programs, which is expected to aid in growth of the
market. For instance, British Columbia Center for Disease Control sponsored
doxycycline (drug) studies for indication of syphilis and other sexually
transmitted infection, which is in early phase I clinical trial as of 2016.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/sexually-transmitted-diseases-stds-treatment-market-2005
Moreover, increasing governmental
initiatives to spread awareness through organization of campaigns and free
diagnostic camps is also expected to augment growth of the STDs treatment
market. For instance, Centers for Disease Control and Prevention (CDC) launched
Improving Sexually Transmitted Disease Programs through Assessment, Assurance,
Policy Development, and Prevention Strategies, or STD-AAPPS, in 2014. Moreover,
in 2018, Thunder Bay Group—HIV / AIDS / hepatitis C education and support
services provider— expanded the access of hepatitis C medicine for individuals
with level 2 hepatitis C, after
negotiating with the provinces and drug manufacturers.
However, growth of the sexually
transmitted disease treatment market is expected to be restrained by low rate
of screening for diseases and late diagnosis of the disease such as HIV.
Sexually Transmitted Diseases
Treatment market – Competitor
Major players in highly
fragmented sexually transmitted diseases treatment market are Merck & Co.
Inc., Pfizer INC, GlaxoSmithKline Plc, Vertex Pharmaceuticals, Roche, Gilead
Sciences Inc., AbbVie Inc., Johnson & Johnson and Bristol-Myers Squibb. Key
players in sexually transmitted disease treatment market are focusing on
adopting strategies such as mergers and collaborations for expanding their
research for candidate drugs. For instance, in 2017, the drug Zoloflodacin
entered into clinical trials, as a result of partnership between Global
Antibiotic Research and Development Partnership (GARDP) and Entasis
Therapeutics. Moreover, in March 2018, Inovio Pharmaceuticals, Inc. entered
into a deal with ApolloBio Corp., which have the exclusive rights for
development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA
immunotherapy product for pre-cancer indication.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2005
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
I am here to appreciate Dr OGU for using his herbal medicine to cure my Herpes virus. Is about 2 years and 6 months now I have been living with this virus and it has been a serious problem to me, I was so confused cause i have been taking several drugs to be cured but all of my effort was in vain,one morning i was browsing through the internet then i saw several testimonies about Dr. OGU curing people from Herpes virus and immediately i contacted Dr. on his email: drogugusolutionhome@gmail.com , i told him about my troubles and he told me that i must be cured, he gave me some instructions and which i rightly followed. so he prepared a herbal medicine and sent it to me via DHL which i used for 2 weeks and i was cured everything was like a dream to me and my Herpes virus was totally gone, dr .OGU , God bless you and give you more power and ability for more cures.i dont know if there is any one out there suffering for herpes virus or any of these diseases.. DIABETES, CANCER,GENITAL AND SIMPLEX HERPES,LOW SPERMS COUNT,SYPHILIS, HIV/AIDS, FIBROID,COPD,MENINGITIS,HEPATITIS A,B [HBV] DISEASES, CHLAMYDIA, .etc why don't you contact dr. Ogu today and be free from your diseases because he is very good and honest Doctor. contact him via email; drogugusolutionhome@gmail.com or text/call via: +1 (719) 629 0982
ReplyDelete